Glynos Nicolas G, Baker Anne, Aday Jacob S, Kruger Daniel, Boehnke Kevin F, Lake Stephanie, Lucas Philippe
Anesthesiology Department, University of MichiganMedical School, Ann Arbor, MI, USA.
Chronic Pain and Fatigue Research Center, University of MichiganMedical School, Ann Abor, MI, USA.
Br J Pain. 2025 Feb 11:20494637251319497. doi: 10.1177/20494637251319497.
Psychedelic substances have shown preliminary efficacy for several neuropsychiatric disorders and are currently being investigated for chronic pain conditions. However, few studies have investigated outcomes of naturalistic psychedelic use among individuals with chronic pain, and none have assessed psychedelic-related changes in substance use patterns in this population. In a cross-sectional survey of adults who reported using psychedelics to self-treat a chronic pain condition ( = 466; 46.1% women), we investigated changed substance use patterns and self-reported outcomes on physical and mental health following use of a psychedelic. Most (86.3%; = 391/453) indicated that they ceased or decreased use of one or more non-psychedelic substances "as a result of" psychedelic use, and 21.2% ( = 83/391) indicated that the decrease in use persisted for more than 26 weeks after psychedelic use. Alcohol (71.1%; = 226/318) and prescription opioids (64.1%; = 100/156) had the highest proportions for ceased/decreased use. Illicit opioids (27.8%; = 22/79) and cannabis (21.5%; = 78/362) had the highest proportions for increased/initiated use. In multivariate regression modeling, having a motivation to reduce one's substance use was positively associated with ceasing/decreasing substance use ( < .001). Perceptions of health outcomes following psychedelic use were broadly positive, and psilocybin was reported to be the most effective substance for both physical and mental health symptoms. Although limited by a cross-sectional study design, findings from this large sample merit future investigation into the benefits and risks of naturalistic psychedelic use among individuals with chronic pain.
迷幻物质已在几种神经精神疾病中显示出初步疗效，目前正在针对慢性疼痛状况进行研究。然而，很少有研究调查慢性疼痛患者自然使用迷幻物质的结果，也没有研究评估该人群中与迷幻物质相关的物质使用模式变化。在一项对报告使用迷幻物质自我治疗慢性疼痛状况的成年人的横断面调查中（n = 466；46.1%为女性），我们调查了使用迷幻物质后物质使用模式的变化以及自我报告的身心健康结果。大多数人（86.3%；n = 391/453）表示，他们“由于”使用迷幻物质而停止或减少了一种或多种非迷幻物质的使用，21.2%（n = 83/391）表示使用减少在使用迷幻物质后持续超过26周。酒精（71.1%；n = 226/318）和处方阿片类药物（64.1%；n = 100/156）停止/减少使用的比例最高。非法阿片类药物（27.8%；n = 22/79）和大麻（21.5%；n = 78/362）增加/开始使用的比例最高。在多变量回归模型中，有减少物质使用的动机与停止/减少物质使用呈正相关（P <.001）。使用迷幻物质后对健康结果的看法总体上是积极的，据报告裸盖菇素对身心健康症状都是最有效的物质。尽管受横断面研究设计的限制，但这个大样本的研究结果值得未来对慢性疼痛患者自然使用迷幻物质的益处和风险进行调查。
